CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

BACKGROUND: Adrenocortical carcinoma (ACC) is an extremely rare, aggressive tumor with few effective therapeutic options or drugs. Mitotane (Mtn), which is the only authorized therapeutic drug, came out in 1970 and is still the only first-line treatment for ACC in spite of serious adverse reaction a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Liwen, Yang, Yihui, Li, Wan, Zheng, Xiangjin, Liu, Jinyi, Li, Sha, Yang, Hong, Zhang, Yizhi, Ge, Binbin, Zhang, Sen, Fu, Weiqi, Dong, Dexin, Du, Guanhua, Wang, Jinhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528181/
https://www.ncbi.nlm.nih.gov/pubmed/36184616
http://dx.doi.org/10.1186/s12967-022-03641-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528181/
https://www.ncbi.nlm.nih.gov/pubmed/36184616
http://dx.doi.org/10.1186/s12967-022-03641-y

Ejemplares similares